Role of MicroRNA Profile Modifications in Hepatitis C Virus-Related Mixed Cryoglobulinemia

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Fognani, Elisa ^a   Giannini, Carlo ^a   Piluso, Alessia ^a   Gragnani, Laura ^a   Monti, Monica ^a   Caini, Patrizio ^a   Ranieri, Jessica ^a   Urraro, Teresa ^a   Triboli, Elisa ^a   Laffi, Giacomo ^a   Zignego, Anna Linda ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 146A; MICRORNA 155; MICRORNA 21; MICRORNA 26B; MICRORNA LET 7D; UNCLASSIFIED DRUG; MIRN26A MICRORNA, HUMAN; TRANSCRIPTOME;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; CRYOGLOBULINEMIA; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; AGED; BLOOD; CASE CONTROL STUDY; COMPLICATION; GENETICS; HEPACIVIRUS; LYMPHOPROLIFERATIVE DISEASE; MIDDLE AGED; VIROLOGY;

HEPATITIS C VIRUS;

AGED; CASE-CONTROL STUDIES; CRYOGLOBULINEMIA; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; MALE; MICRORNAS; MIDDLE AGED; TRANSCRIPTOME;

EID: 84877017662     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062965     Document Type: Article

References (59)

1. Ferri C, Longombardo G, La Civita L, Greco F, Lombardini F, et al. (1994) Hepatitis C virus chronic infection as a common cause of mixed cryoglobulinaemia and autoimmune liver disease. J Intern Med 236: 31-36.
2. Ferri C, Zignego AL, Bombardieri S, La Civita L, Longombardo G, et al. (1995) Etiopathogenetic role of hepatitis C virus in mixed cryoglobulinemia, chronic liver diseases and lymphomas. Clin Exp Rheumatol 13Suppl 13: S135-140.
3. Zignego AL, Ferri C, Monti M, LaCivita L, Giannini C, et al. (1995) Hepatitis C virus as a lymphotropic agent: evidence and pathogenetic implications. Clin Exp Rheumatol 13: S33-37.
4. Sansonno D, De Vita S, Iacobelli AR, Cornacchiulo V, Boiocchi M, et al. (1998) Clonal analysis of intrahepatic B cells from HCV-infected patients with and without mixed cryoglobulinemia. J Immunol 160: 3594-3601.
5. Zignego AL, Ferri C, Pileri SA, Caini P, Bianchi FB, (2007) Extrahepatic manifestations of Hepatitis C Virus infection: A general overview and guidelines for a clinical approach. Dig Liver Dis 39: 2-17.
6. Craxi A, Laffi G, Zignego AL, (2008) Hepatitis C virus (HCV) infection: A systemic disease. Mol Aspects Med 29: 85-95.
7. Zignego AL, Giannini C, Ferri C, (2007) Hepatitis C virus-related lymphoproliferative disorders: an overview. World J Gastroenterol 13: 2467-2478.
8. Zignego AL, Macchia D, Monti M, Thiers V, Mazzetti M, et al. (1992) Infection of peripheral mononuclear blood cells by hepatitis C virus [see comments]. J Hepatol 15: 382-386.
9. Ferri C, Monti M, La Civita L, Longombardo G, Greco F, et al. (1993) Infection of peripheral blood mononuclear cells by hepatitis C virus in mixed cryoglobulinemia. Blood 82: 3701-3704.
10. Zignego AL, Giannini C, Gragnani L, (2012) HCV and lymphoproliferation. Clin Dev Immunol 2012: 980942.
11. Hermine O, Lefrere F, Bronowicki JP, Mariette X, Jondeau K, et al. (2002) Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 347: 89-94.
12. Kawamura Y, Ikeda K, Arase Y, Yatsuji H, Sezaki H, et al. (2007) Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C. Am J Med. 120: 1034-1041.
13. Knight GB, Gao L, Gragnani L, Elfahal MM, De Rosa FG, et al. (2010) Detection of WA B cells in hepatitis C virus infection: a potential prognostic marker for cryoglobulinemic vasculitis and B cell malignancies. Arthritis Rheum 62: 2152-2159.
14. Bianchettin G, Bonaccini C, Oliva R, Tramontano A, Cividini A, et al. (2007) Analysis of hepatitis C virus hypervariable region 1 sequence from cryoglobulinemic patients and associated controls. J Virol 81: 4564-4571.
15. Gragnani L, Piluso A, Giannini C, Caini P, Fognani E, et al. (2011) Genetic determinants in hepatitis C virus-associated mixed cryoglobulinemia: role of polymorphic variants of BAFF promoter and Fcgamma receptors. Arthritis Rheum 63: 1446-1451.
16. De Re V, Caggiari L, Simula MP, De Vita S, Mazzaro C, et al. (2007) Role of the HLA class II: HCV-related disorders. Ann N Y Acad Sci 1107: 308-318.
17. Alevizos I, Alexander S, Turner RJ, Illei GG, (2011) MicroRNA expression profiles as biomarkers of minor salivary gland inflammation and dysfunction in Sjogren's syndrome. Arthritis Rheum 63: 535-544.
18. O'Connell RM, Rao DS, Chaudhuri AA, Baltimore D, (2010) Physiological and pathological roles for microRNAs in the immune system. Nat Rev Immunol 10: 111-122.
19. Kotani A, Harnprasopwat R, Toyoshima T, Kawamata T, Tojo A, (2010) miRNAs in normal and malignant B cells. Int J Hematol 92: 255-261.
20. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P, (2005) Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 309: 1577-1581.
21. Kumar A, (2011) MicroRNA in HCV infection and liver cancer. Biochim Biophys Acta 1809: 694-699.
22. Cheng CJ, Slack FJ, (2012) The duality of oncomiR addiction in the maintenance and treatment of cancer. Cancer J 18: 232-237.
23. Zhang B, Pan X, Cobb GP, Anderson TA, (2007) microRNAs as oncogenes and tumor suppressors. Dev Biol 302: 1-12.
24. Esquela-Kerscher A, Slack FJ, (2006) Oncomirs- microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269.
25. Bouteloup M, Verney A, Rachinel N, Callet-Bauchu E, Ffrench M, et al. (2012) MicroRNA expression profile in splenic marginal zone lymphoma. Br J Haematol 156: 279-281.
26. Peveling-Oberhag J, Crisman G, Schmidt A, Doring C, Lucioni M, et al. (2012) Dysregulation of global microRNA expression in splenic marginal zone lymphoma and influence of chronic hepatitis C virus infection. Leukemia 26(7): 1654-62.
27. Di Lisio L, Martinez N, Montes-Moreno S, Piris-Villaespesa M, Sanchez-Beato M, et al. (2012) The role of miRNAs in the pathogenesis and diagnosis of B-cell lymphomas. Blood 120: 1782-1790.
28. Gramantieri L, Fornari F, Callegari E, Sabbioni S, Lanza G, et al. (2008) MicroRNA involvement in hepatocellular carcinoma. J Cell Mol Med 12: 2189-2204.
29. Ji J, Shi J, Budhu A, Yu Z, Forgues M, et al. (2009) MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 361: 1437-1447.
30. Nakasa T, Miyaki S, Okubo A, Hashimoto M, Nishida K, et al. (2008) Expression of microRNA-146 in rheumatoid arthritis synovial tissue. Arthritis Rheum 58: 1284-1292.
31. Pauley KM, Satoh M, Chan AL, Bubb MR, Reeves WH, et al. (2008) Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Res Ther 10: R101.
32. Stanczyk J, Pedrioli DM, Brentano F, Sanchez-Pernaute O, Kolling C, et al. (2008) Altered expression of MicroRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis. Arthritis Rheum 58: 1001-1009.
33. Hughes T, Sawalha AH, (2011) The role of epigenetic variation in the pathogenesis of systemic lupus erythematosus. Arthritis Res Ther 13: 245.
34. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 57: 167-185.
35. Ghany MG, Strader DB, Thomas DL, Seeff LB, (2009) Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49: 1335-1374.
36. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 55: 245-264.
37. Bedossa P, Poynard T, (1996) An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 24: 289-293.
38. Zignego AL, Giannelli F, Marrocchi ME, Mazzocca A, Ferri C, et al. (2000) T(14;18) translocation in chronic hepatitis C virus infection. Hepatology 31: 474-479.
39. Zignego AL, Ferri C, Giannini C, Monti M, La Civita L, et al. (1996) Hepatitis C virus genotype analysis in patients with type II mixed cryoglobulinemia. Ann Intern Med 124: 31-34.
40. Andreone P, Zignego AL, Cursaro C, Gramenzi A, Gherlinzoni F, et al. (1998) Prevalence of monoclonal gammopathies in patients with hepatitis C virus infection. Ann Intern Med 129: 294-298.
41. Pietrogrande M, De Vita S, Zignego AL, Pioltelli P, Sansonno D, et al. (2011) Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. Autoimmun Rev 10: 444-454.
42. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, et al. (1994) A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group [see comments]. Blood 84: 1361-1392.
43. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
44. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, et al. (2008) Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 141: 672-675.
45. Qi R, Weiland M, Gao XH, Zhou L, Mi QS (2012) Identification of endogenous normalizers for serum microRNAs by microarray profiling: U6 small nuclear RNA is not a reliable normalizer. Hepatology 55: 1640-1642; author reply 1642-1643.
46. Tang Y, Luo X, Cui H, Ni X, Yuan M, et al. (2009) MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum 60: 1065-1075.
47. Li S, Liang Z, Xu L, Zou F, (2012) MicroRNA-21: a ubiquitously expressed pro-survival factor in cancer and other diseases. Mol Cell Biochem 360: 147-158.
48. Leng RX, Pan HF, Qin WZ, Chen GM, Ye DQ, (2011) Role of microRNA-155 in autoimmunity. Cytokine Growth Factor Rev 22: 141-147.
49. Kluiver J, Poppema S, de Jong D, Blokzijl T, Harms G, et al. (2005) BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J Pathol 207: 243-249.
50. van den Berg A, Kroesen BJ, Kooistra K, de Jong D, Briggs J, et al. (2003) High expression of B-cell receptor inducible gene BIC in all subtypes of Hodgkin lymphoma. Genes Chromosomes Cancer 37: 20-28.
51. Machida K, Cheng KT, Sung VM, Shimodaira S, Lindsay KL, et al. (2004) Hepatitis C virus induces a mutator phenotype: enhanced mutations of immunoglobulin and protooncogenes. Proc Natl Acad Sci U S A 101: 4262-4267.
52. Ito M, Murakami K, Suzuki T, Mochida K, Suzuki M, et al. (2010) Enhanced expression of lymphomagenesis-related genes in peripheral blood B cells of chronic hepatitis C patients. Clin Immunol 135: 459-465.
53. Petrarca A, Rigacci L, Caini P, Colagrande S, Romagnoli P, et al. (2010) Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease. Blood 116: 335-342.
54. Piluso A, Giannini C, Fognani E, Gragnani L, Caini P, et al. (2013) Value of IL28B genotyping in patients with HCV-related mixed cryoglobulinemia: results of a large, prospective study. J Viral Hepat 20: e107-114.
55. Takeno A, Takemasa I, Doki Y, Yamasaki M, Miyata H, et al. (2008) Integrative approach for differentially overexpressed genes in gastric cancer by combining large-scale gene expression profiling and network analysis. Br J Cancer 99: 1307-1315.
56. Nassirpour R, Shao L, Flanagan P, Abrams T, Jallal B, et al. (2010) Nek6 mediates human cancer cell transformation and is a potential cancer therapeutic target. Mol Cancer Res 8: 717-728.
57. Zhang Z, Florez S, Gutierrez-Hartmann A, Martin JF, Amendt BA, (2010) MicroRNAs regulate pituitary development, and microRNA 26b specifically targets lymphoid enhancer factor 1 (Lef-1), which modulates pituitary transcription factor 1 (Pit-1) expression. J Biol Chem 285: 34718-34728.
58. Gutierrez A Jr, Tschumper RC, Wu X, Shanafelt TD, Eckel-Passow J, et al. (2010) LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B-cell lymphocytosis. Blood 116: 2975-2983.
59. Cubedo E, Gentles AJ, Huang C, Natkunam Y, Bhatt S, et al. (2012) Identification of LMO2 transcriptome and interactome in diffuse large B-cell lymphoma. Blood 119: 5478-5491.